Whooping cough Infections and Infestations Whooping cough
Conditions
Interventions
The combination vaccine diphtheria, tetanus, pertussis acellular vaccination, poliomyelitis (DTPacv-IPV) (Boostrix polio™, 0.5 ml) produced by GlaxoSmithKline (GSK) containing a three-component ACV (p
Sponsors
National Institute of Public Health and Environmental Protection (RIVM) (Netherlands)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy 8 to 9 year old children, either sex 2. Received four vaccinations at 2, 3, 4 and 11 months with diphtheria, tetanus, pertussis whole cell vaccine, poliomyelitis - haemophilus influenzae type b (DTPwcv IPV-Hib) 3. Received a booster vaccination at 4 years old with a three component ACV
Exclusion criteria
Exclusion criteria: Any of the following criteria will exclude a volunteer from participation, at start of the study: 1. Present evidence of serious disease(s) demanding immunosuppressive medical treatment, like corticosteroids that might interfere with the results of the study within three months 2. Any known primary or secondary immunodeficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameters will be pertussis specific memory B- and T-cell responses as well as antibody levels and affinity against the various proteins of pertussis and the other components of the DTPacv-IPV-Hib vaccine. | — |
Secondary
| Measure | Time frame |
|---|---|
| If there are enough lymphocytes, the immune response (memory B- and T-cells and antibody responses) to other vaccine preventable diseases, like measles, mumps, diphtheria, tetanus and polio will also be measured. | — |
Countries
Netherlands
Outcome results
None listed